whocc logo
ppri logo
goeg logo

Pharmaceutical Pricing and Reimbursement Policies:
Challenges Beyond the Financial Crisis

3rd International PPRI Conference

12-13 October 2015, Vienna

Venue:
Palais Niederösterreich, Herrengasse 13, 1010 Wien

Conference website: http://whocc.goeg.at/Conference2015
Contact: ppriconference@goeg.at


General Downloads

PROGRAMME

Day 1: Monday, 12 October 2015 (09:00-17:30)

8:00 – 9:00
Registration and Coffee
9:00 – 10:00
Welcome
  • Austrian Federal Ministry of Health, Minister Sabine Oberhauser
  • Gesundheit Österreich GmbH, General Manager Georg Ziniel
  • WHO, Director of the Essential Medicines and Health Products Department Kees de Joncheere
  • WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Sabine Vogler
Facilitator: Lena Lepuschütz, GÖG (Austrian Public Health Institute)
10:00 - 10:45

Key Note: Affordable innovation - Future Directions in Pharmaceutical Policy

Suzanne Hill, Senior Adviser, Policy Access and Use, Essential medicines and health products Department, WHO HQ

Commentary:
 
Menno Arnout, AIM/International Association of Mutual Benefit Societies
Valérie Paris, Organisation for Economic Co-operation and Development (OECD), France

Facilitator: Lena Lepuschütz, GÖG (Austrian Public Health Institute)

10:45 - 11:15
Coffee Break
11:15 – 12:15
Stakeholder Roundtable: Pharmaceutical Policies in Crisis? Needs for Change
  • Francis Arickx, Social Health Insurance (INAMI), Belgium
  • Richard Bergström, European Federation of Pharmaceutical Industries and Associations (EFPIA)
  • Tim Reed, Health Action International (HAI) Global
  • Jan Mazag, State Institute for Drug Control (SUKL), Slovakia

Commentary:
 
Pieter Dylst, European Generic and Biosimilar Medicines Association (EGA)
Catherine Day, Irish Pharmacy Union (on behalf of PGEU)

Facilitator: Hans Hogerzeil, University Groningen

12:15 – 12:30
Outlook on Conference
Lena Lepuschütz, GÖG (Austrian Public Health Institute)
12:30 - 14:00
Lunch Break
14:00 – 15:15
Breakout Session 1

Strand I: Challenges and Opportunities for Pharmaceutical Policies

  • Key Note: WHO Priority Medicines for Europe and the World: Setting a public-health-based medicines development agenda
    Veronika Wirtz, Boston University, USA
    • Abstract Presentation 1: Adapting pharmaceutical reimbursement policies to manage spending on high-priced drugs
      Elizabeth Docteur, Elizabeth Docteur Consulting, US
    • Abstract Presentation 2: Financial based agreements and performance based agreements: the Belgian experience
      Kim Pauwels, KU Leuven, Belgium (Young Researcher Award)
    Facilitator: Christine Leopold, Harvard Medical School and Harvard Pilgrim Institute, USA

Strand II: Policies beyond the Crisis: Lessons Learned

  • Key Note: Pharmaceutical Policies in Australia and New Zealand
    Zaheer-Ud-Din Babar, University of Auckland, New Zealand
    • Abstract Presentation 1: Highly innovative drugs in the Czech Republic: retrospective analysis of impact on early market entry, regular reimbursement system entry and public pharmaceutical expenditure
      Juraj Slabý, State Institute for Drug Control, Prague, Czech Republic
    • Abstract Presentation 2: Impact of discounts on medicine prices
      Peter Schneider, GÖG (Austrian Public Health Institute), Austria
    Facilitator: Suzanne Hill, Senior Adviser, Policy Access and Use, Essential medicines and health products Department, WHO HQ

Strand III: Policy Cooperation and Interface Issues

  • Key Note: Scottish collaboration to integrate medicine therapy between out-patient and in-patient sectors
    Ken Paterson, University of Glasgow, Scotland

    • Abstract Presentation 1: Determinants of differences in utilisation of cancer medicines in Belgium, Scotland and Sweden.
      Alessandra Ferrario, London School of Economics (LSE), England
    • Abstract Presentation 2: A cost/benefit analysis of self-care initiatives in the European Union – who gains, who loses?
      Julia Bobek, GÖG (Austrian Public Health Institute), Austria
    Facilitator: Sabine Vogler, Head of WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, GÖG/Austrian Public Health Institute
15:15 – 15.45
Poster walk during coffee break
15.45 – 17.00
Moderated Poster Session

Strand I: Challenges and Opportunities for Pharmaceutical Policies

  • Poster Presentations
    • 1: Unintended consequences of co-payment regulations in Belgium: the case of atorvastatin
      Jessica Fraeyman, Department of Epidemiology and Social Medicine, Research Unit of Medical Sociology and Health Policy, University Antwerp, Belgium
    • 2: Impact of Generic Price Linkage System and Reference Price System on Prices of Pharmaceuticals – Comparison of Austria and Finland
      Jaana Martikainen, Social Insurance Institution, Finland
    • 3: Availability and prices of essential medicines for chronic diseases in older people in the Asia Pacific Region
      Agnes Vitry, University of South Australia, Australia
    • 4: Unintended consequences of pharmaceutical policies: A three country qualitative study of Namibia, South Africa and Ghana insurance reimbursement models
      Emmanuel K Eghan, Management Sciences for Health (MSH), Arlington, USA
    Facilitator: Anna Bucsics, University of Vienna, Austria

Strand II: Policies beyond the Crisis: Lessons Learned

  • Poster Presentations
    • 1: Transitioning to a national health system in Cyprus: a stakeholder analysis of pharmaceutical policy reform
      Olivier Wouters, London School of Economics (LSE), England
    • 2: Impact of delisting OTC medicines from reimbursement list in Czech Republic
      Petra Chytilová, State Institute of Drug Control (SIDC), Czech Republic
    • 3: The impact of Ghana’s National Health Insurance Scheme (NHIS) median pharmaceutical pricing methodology and reimbursement policy on the pharmaceutical system
      Dumebi Mordi, Management Sciences for Health (MSH), Arlington, USA
    • 4: The Effect of Pricing Regulation on Prescription Frequency of Compounded Drugs, Medical Foods, and Convenience Packages in the US
      Tracy Lin, University of California, USA
    Facilitator: Valérie Paris, OECD, France

Strand III: Policy Cooperation and Interface Issues

  • Poster Presentations
    • 1: Retrospective financial analysis of medicines reimbursement services in community pharmacy
      Elena Chitan, State University of Medicine and Pharmacy 'Nicolae Testemitanu, Moldova'
    • 2: Multi-Indication Pricing: Pros, Cons and Applicability to the UK
      Jorge Mestre-Ferrandiz, Office of Health Economics, England
    • 3: A forecasting model for drug utilization and expenditure integrating a Cellular Automata model with the Budget Impact Analysis approach. Preliminary results.
      Roberta Joppi, Local Health Authority of Verona - Veneto region, Italy
    • 4: Policy options to deal with high-cost medicines – Survey with European policy-makers
      Nina Zimmermann, GÖG (Austrian Public Health Institute), Austria
    Facilitator: Veronika Wirtz, Boston University, USA
17.00 – 17.30
Key Note: New WHO Report ‘Access to new medicines in Europe: Technical review of policy initiatives and opportunities for collaboration and research’

Hanne Bak Pedersen, WHO Regional Office for Europe

Facilitator: Aukje Mantel-Teeuwisse, Utrecht University, the Netherlands

17:30 – 18:30
Reception

Day 2: Tuesday 13 October 2015 (09:00 - 15:30)

8:00 - 9:00
Early Bird Session: Meet the Editors
  • Journal of Pharmaceutical Policy and Practice (JOPPP), Zaheer-Ud-Din Babar
  • PharmacoEconomics, Chris Carswell (online)
  • Health Policy, Panos Kanavos
  • Generics and Biosimilars Initiative Journal (GaBI), Arnold Vulto
  • Bulletin of the World Health Organization, Laragh Gollogly
Facilitator: Aukje Mantel-Teeuwisse, Utrecht University
9:00 – 10:00
Country Poster Presentations

European Union/European Economic Area Countries

  • Austria: Margit Gombocz, GÖG (Austrian Public Health Institute) and Robert Sauermann, HVB (Main Association of Austrian Social Security Institutions)
  • Cyprus: Helena Panayiotopoulou, Pharmaceutical Services, Ministry of Health
  • Ireland: Kate Mulvenna, Health Service Executive
  • Sweden: Peter Skiöld, The Dental and Pharmceutical Benefits Agency (TLV)
Facilitator: Robin Šebesta, State Institute for Drug Control, Czech Republic

Other European Countries

  • Norway: Helga Festoy, Norwegian Medicines Agency
  • Russia: Liudmila Bezmelnitsyna, National Institution for Public Health
  • Switzerland: Jörg Indermitte, Federal Office of Public Health
  • Ukraine: Olga Sadovnycha, State Expert Centre of the Ministry of Health
Facilitator: Guillaume Dedet, WHO Regional Office for Europe

Non-European Countries

  • Canada: Tanya Ptashnik, Patented Medicine Prices Review Board (PMPRB)
  • Colombia: Angela Acosta Santamaria, Pontificia Universidad Javeriana
  • Mexico: Yared Santa-Ana-Tellez, Utrecht University, the Netherlands
  • South Africa: Ntobeko Mpanza, National Department of Health

Facilitator: Veronika Wirtz, Boston University, USA

10:00 – 10:30
Poster walk during coffee break
10:30 – 12:00
Breakout Session 2

Strand I: Challenges and Opportunities for Pharmaceutical Policies

  • Key Note: Biosimilars – Same quality, lower price, improved patient access
    Arnold Vulto, Erasmus University Hospital, Netherlands

    • Abstract Presentation 3: Access to subsidised medicines, cost of medicines and health outcomes: Exploring general practitioners’ perceptions and experiences
      Zaheer-Ud-Din Babar, University of Auckland, New Zealand
    • Abstract Presentation 4: Using a Multiple Criteria Decision Analysis (MCDA) framework to make coverage decisions: an experimental case study on metastatic colorectal cancer
      Aris Angelis, London School of Economics (LSE), England
    • Abstract Presentation 5: Approval, reimbursement and pricing of high cost cancer medicines in Australia
      Agnes Vitry, University of South Australia, Australia
    Facilitator: Hanne Bak Pedersen, WHO Regional Office for Europe

Strand II: Policies beyond the Crisis: Lessons Learned

  • Key Note: The Greek experience – Lessons learned
    Panos Kanavos, London School of Economics, UK

    • Abstract Presentation 3: Introduction of generic substitution and reference pricing in Ireland: early effects on state pharmaceutical expenditure and generic penetration, and associated success factors
      Susan Spillane, National Centre for Pharmacoeconomics, Ireland
    • Abstract Presentation 4: Price changes of antibiotics and perceived substitutes in the context of OTC policy changes in Mexico and Brazil
      Yared Santa-Ana-Tellez, Utrecht University, the Netherlands
    • Abstract Presentation 5: Socioeconomic Determinants of Medicines Use in Central Eastern Europe: The Role of Pharmaceutical Policy in Reducing Inequalities
      Susanne Mayer, Department of Health Economics, Centre for Public Health, Medical University of Vienna, Austria
    Facilitator: Aukje Mantel-Teeuwisse, Utrecht University, the Netherlands

Strand III: Policy Cooperation and Interface Issues

  • Key Note: The sofosbuvir case – Lessons learned
    Florent Dromzée, Ministry of Health, France
    • Abstract Presentation 3: Why we should have more collaboration on HTA in Europe: The example of sofosbuvir
      Wim Goettsch, National Health Care Institute, the Netherlands
    • Abstract Presentation 4 : Criteria for Inclusion into the Essential Medicines List
      Nicola Magrini, World Health Organization, Switzerland

    • Abstract Presentation 5: Collaborative models for increasing efficiency of early drug assessment
      Anna Nachtnebel, Ludwig Boltzmann Institute for Health Technology Assessment, Austria
    Facilitator: Hans Hogerzeil, University Groningen, the Netherlands
12:00 – 13:30
Lunch
13:30 – 15:30
Afternoon session
Facilitator: Kees de Joncheere, WHO Headquarter, Switzerland
13:30 - 14:30
Key Note: Perspectives for the Future
  • Andy Gray, University of KwaZulu-Natal, South Africa
14:30 – 15:00
Closing Commentary: Patients have the last word?
  • Nicola Bedlington, European Patients’ Forum

15:00 – 15:30
Conclusions, awards and closure
  • Sabine Vogler, WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Austria

***